Corcept Therapeutics Inc
CORTNASDAQStock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors
Corcept Therapeutics Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation8
- Growth95
- Profitability60
- Quality67
- Debt100
- Stability100
- ✓It has more cash than debt.
- ✓Revenue grew 23.7% a year over 3 years.
- ✓The analysts' average target is 61% above the price.
- !The stock is expensive: you pay 194.6 USD for 1 USD of annual earnings.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveFor 1 USD of annual earnings you pay 194.6 USD. Based on next year's estimates 20.9 USD.
- P/E
- 194.6×
- P/S
- 11.4×
- EV/EBITDA
- 1,128.1×
Is the company growing?
GrowingRevenue over 3 years grew 23.7% a year. Last year 31.7%.
Does it make money?
WeakChart CORT
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
6JS Jim Simons Renaissance Technologies | 0.63% |
CA Cliff Asness AQR Capital Management | 0.08% |
RD Ray Dalio Bridgewater Associates | 0.02% |
JG Joel Greenblatt Gotham Asset Management | 0.01% |
Šn Švýcarská národní banka Swiss National Bank | 0.01% |
Ns Norský státní fond Norges Bank | 0% |
Frequently asked questions
How much is Corcept Therapeutics Inc (CORT) stock?
Corcept Therapeutics Inc shares trade at $87.59, +0.53% over the last trading day. The price is delayed.
What is the market cap of Corcept Therapeutics Inc?
The market cap of Corcept Therapeutics Inc is about $9.5B and its price-to-earnings ratio (P/E) is 194.6.
Which big investors hold Corcept Therapeutics Inc?
According to the latest 13F filings, 6 of 87 tracked investors hold Corcept Therapeutics Inc, for example Jim Simons, Cliff Asness, Ray Dalio.
When will Corcept Therapeutics Inc report its next results?
The next earnings report of Corcept Therapeutics Inc is expected on 3 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.